GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?

The Lancet Diabetes and Endocrinology

Volumn 4, Issue 12, 2016, Pages 963-964

  Nauck, Michael A ^a   Meier, Juris J ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DAPAGLIFLOZIN; EMPAGLIFLOZIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; SODIUM GLUCOSE COTRANSPORTER 2;

COMBINATION CHEMOTHERAPY; DIABETIC KETOACIDOSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERPHAGIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84994509821     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(16)30263-7     Document Type: Note

References (10)

1. 1 Frias, J, Guja, C, hardy, E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol, 2016 published online Sept 16. http://dx.doi.org/10.1016/S2213-8587(16)30267-4.
2. 2 Nauck, M, Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 18 (2016), 203–216.
3. 3 Abdul-Ghani, MA, Norton, L, DeFronzo, RA, Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 32 (2011), 515–531.
4. 1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med 27 (2010), 309–317.
5. 5 Ferrannini, G, Hach, T, Crowe, S, Sanghvi, A, Hall, KD, Ferrannini, E, Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care 38 (2015), 1730–1735.
6. 6 Peters, AL, Buschur, EO, Buse, JB, Cohan, P, Diner, JC, Hirsch, IB, Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38 (2015), 1687–1693.
7. 7 Ferrannini, E, Mark, M, Mayoux, E, CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 39 (2016), 1108–1114.
8. 8 Marso, SP, Daniels, GH, Brown-Frandsen, K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
9. 9 Zinman, B, Wanner, C, Lachin, JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
10. 10 Nauck, MA, Meier, JJ, Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells?. Nat Rev Endocrinol 7 (2011), 193–195.